

Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants

Supplementary Appendix

Authors: Hung Fu Tseng, PhD,^{1,2,*} Bradley K. Ackerson, MD,¹ Yi Luo, PhD,¹ Lina S. Sy, MPH,¹ Carla A. Talarico, PhD,³ Yun Tian, MS,¹ Katia J. Bruxvoort, PhD,⁴ Julia E. Tubert, MPH,¹ Ana Florea, PhD,¹ Jennifer H. Ku, PhD,¹ Gina S. Lee, MPH,¹ Soon Kyu Choi, MPH,¹ Harpreet S. Takhar, MPH,¹ Michael Aragones, MD,¹ Lei Qian, PhD¹


Affiliations: ¹Department of Research and Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles Ave., Pasadena, CA, 91101, USA; ²Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, 98 S. Los Robles Ave., Pasadena, CA, 91101, USA; ³Moderna Inc., 200 Technology Square, Cambridge, MA, 02139, USA; ⁴Department of Epidemiology, University of Alabama at Birmingham, 1665 University Blvd., Birmingham, AL, 35233, USA

Contents

Supplementary Figure 1. Flow chart for 1-dose, 2-dose, and 3-dose mRNA-1273 vaccine test negative design..... 3

Supplementary Table 1. Characteristics of SARS-CoV-2 test positive cases and test negative controls, by variant (1-dose analysis) 4

Supplementary Figure 1. Flow chart for 1-dose, 2-dose, and 3-dose mRNA-1273 vaccine test negative design



* There were 47 cases excluded from the 1-dose analysis due to inability to find 5 fully matched controls.

Supplementary Table 1. Characteristics of SARS-CoV-2 test positive cases and test negative controls, by variant (1-dose analysis)

	Delta			Omicron		
	Test Positive N=2053	Test Negative N=10265	p-value/ASD	Test Positive N=1515	Test Negative N=7575	p-value/ASD
Age at specimen collection date, years			0.49 / 0.02			<0.01 / 0.14
mean (sd)	41.37 (14.27)	41.64 (14.22)		35.18 (12.10)	36.86 (12.14)	
median	40	40		33	35	
Q1, Q3	31, 51	31, 52		25, 43	28, 43	
min, max	18, 89	18, 100		18, 93	18, 93	
Age at specimen collection date, years, n (%)			N/A			N/A
18-44	1268 (61.8%)	6340 (61.8%)		1182 (78.0%)	5910 (78.0%)	
45-64	655 (31.9%)	3275 (31.9%)		305 (20.1%)	1525 (20.1%)	
65-74	100 (4.9%)	500 (4.9%)		25 (1.7%)	125 (1.7%)	
≥75	30 (1.5%)	150 (1.5%)		3 (0.2%)	15 (0.2%)	
Sex, n (%)			N/A			N/A
Female	1100 (53.6%)	5500 (53.6%)		852 (56.2%)	4260 (56.2%)	
Male	953 (46.4%)	4765 (46.4%)		663 (43.8%)	3315 (43.8%)	
Race/Ethnicity, n (%)			N/A			N/A
Non-Hispanic White	820 (39.9%)	4100 (39.9%)		476 (31.4%)	2380 (31.4%)	
Non-Hispanic Black	122 (5.9%)	610 (5.9%)		184 (12.1%)	920 (12.1%)	
Hispanic	887 (43.2%)	4435 (43.2%)		643 (42.4%)	3215 (42.4%)	
Non-Hispanic Asian	61 (3.0%)	305 (3.0%)		61 (4.0%)	305 (4.0%)	
Other/Unknown	163 (7.9%)	815 (7.9%)		151 (10.0%)	755 (10.0%)	
BMI ^b , n (%)			<0.01 / 0.16			<0.01 / 0.14
<18.5	14 (0.7%)	109 (1.1%)		21 (1.4%)	94 (1.2%)	
18.5 - <25	351 (17.1%)	2125 (20.7%)		371 (24.5%)	1637 (21.6%)	
25 - <30	524 (25.5%)	2769 (27.0%)		416 (27.5%)	1981 (26.2%)	
30 - <35	414 (20.2%)	1947 (19.0%)		257 (17.0%)	1456 (19.2%)	
35 - <40	206 (10.0%)	1017 (9.9%)		117 (7.7%)	730 (9.6%)	
40 - <45	85 (4.1%)	453 (4.4%)		44 (2.9%)	308 (4.1%)	
≥45	48 (2.3%)	282 (2.7%)		34 (2.2%)	221 (2.9%)	
Unknown	411 (20.0%)	1563 (15.2%)		255 (16.8%)	1148 (15.2%)	
Smoking ^b , n (%)			<0.01 / 0.13			<0.01 / 0.11
No	1355 (66.0%)	7260 (70.7%)		1111 (73.3%)	5433 (71.7%)	
Yes	354 (17.2%)	1720 (16.8%)		189 (12.5%)	1216 (16.1%)	
Unknown	344 (16.8%)	1285 (12.5%)		215 (14.2%)	926 (12.2%)	
Charlson comorbidity score ^a , n (%)			0.02 / 0.07			<0.01 / 0.14
0	1695 (82.6%)	8278 (80.6%)		1326 (87.5%)	6376 (84.2%)	
1	234 (11.4%)	1181 (11.5%)		146 (9.6%)	769 (10.2%)	
≥2	124 (6.0%)	806 (7.9%)		43 (2.8%)	430 (5.7%)	

Frailty index ^a , n (%)			<0.01 / 0.16			0.01 / 0.10
Quartile 1	499 (24.3%)	2578 (25.1%)		396 (26.1%)	1855 (24.5%)	
Quartile 2	612 (29.8%)	2442 (23.8%)		399 (26.3%)	1882 (24.8%)	
Quartile 3	513 (25.0%)	2595 (25.3%)		394 (26.0%)	1885 (24.9%)	
Quartile 4 (most frail)	429 (20.9%)	2650 (25.8%)		326 (21.5%)	1953 (25.8%)	
Chronic diseases ^a , n (%)						
Kidney disease	28 (1.4%)	210 (2.0%)	0.04 / 0.05	4 (0.3%)	98 (1.3%)	<0.01 / 0.12
Heart disease	22 (1.1%)	169 (1.6%)	0.05 / 0.05	10 (0.7%)	86 (1.1%)	0.10 / 0.05
Lung disease	134 (6.5%)	788 (7.7%)	0.07 / 0.04	99 (6.5%)	557 (7.4%)	0.26 / 0.03
Liver disease	54 (2.6%)	293 (2.9%)	0.58 / 0.01	22 (1.5%)	183 (2.4%)	0.02 / 0.07
Diabetes	122 (5.9%)	667 (6.5%)	0.35 / 0.02	36 (2.4%)	363 (4.8%)	<0.01 / 0.13
Immunocompromised status, n (%)			<0.01 / 0.14			<0.01 / 0.13
No	2033 (99.0%)	9966 (97.1%)		1500 (99.0%)	7371 (97.3%)	
Yes	20 (1.0%)	299 (2.9%)		15 (1.0%)	204 (2.7%)	
HIV/AIDS	1 (5.0%)	16 (5.4%)		1 (6.7%)	11 (5.4%)	
Leukemia/lymphoma, congenital and other immunodeficiencies, asplenia/hyposplenia	8 (40.0%)	86 (28.8%)		8 (53.3%)	68 (33.3%)	
Organ transplant	1 (5.0%)	9 (3.0%)		1 (6.7%)	14 (6.9%)	
Immunosuppressant medications	12 (60.0%)	215 (71.9%)		7 (46.7%)	143 (70.1%)	
Autoimmune conditions ^a , n (%)			0.14 / 0.04			0.13 / 0.05
No	2015 (98.1%)	10020 (97.6%)		1493 (98.5%)	7420 (98.0%)	
Yes	38 (1.9%)	245 (2.4%)		22 (1.5%)	155 (2.0%)	
Rheumatoid arthritis	8 (21.1%)	106 (43.3%)		10 (45.5%)	50 (32.3%)	
Inflammatory bowel disease	13 (34.2%)	53 (21.6%)		5 (22.7%)	50 (32.3%)	
Psoriasis and psoriatic arthritis	15 (39.5%)	76 (31.0%)		5 (22.7%)	42 (27.1%)	
Multiple sclerosis	2 (5.3%)	17 (6.9%)		2 (9.1%)	14 (9.0%)	
Systemic lupus erythematosus	1 (2.6%)	25 (10.2%)		6 (27.3%)	25 (16.1%)	
Pregnancy status at specimen collection date, n (%)			<0.01 / 0.09			<0.01 / 0.16
No	2014 (98.1%)	9929 (96.7%)		1485 (98.0%)	7213 (95.2%)	
Yes	39 (1.9%)	336 (3.3%)		30 (2.0%)	362 (4.8%)	
1st trimester	11 (28.2%)	43 (12.8%)		5 (16.7%)	33 (9.1%)	
2nd trimester	15 (38.5%)	77 (22.9%)		10 (33.3%)	80 (22.1%)	
3rd trimester	13 (33.3%)	216 (64.3%)		15 (50.0%)	249 (68.8%)	
History of COVID-19 ^c , n (%)			<0.01 / 0.66			<0.01 / 0.15
No	2010 (97.9%)	7907 (77.0%)		1259 (83.1%)	5834 (77.0%)	
Yes	43 (2.1%)	2358 (23.0%)		256 (16.9%)	1741 (23.0%)	
History of SARS-CoV-2 molecular test ^c , n (%)			<0.01 / 0.37			0.48 / 0.02
No	743 (36.2%)	2053 (20.0%)		350 (23.1%)	1687 (22.3%)	

Yes	1310 (63.8%)	8212 (80.0%)		1165 (76.9%)	5888 (77.7%)
Number of outpatient and virtual visits ^a , n (%)			<0.01 / 0.27		<0.01 / 0.18
0	325 (15.8%)	1037 (10.1%)		171 (11.3%)	774 (10.2%)
1-4	774 (37.7%)	3263 (31.8%)		598 (39.5%)	2489 (32.9%)
5-10	493 (24.0%)	2663 (25.9%)		386 (25.5%)	1960 (25.9%)
≥11	461 (22.5%)	3302 (32.2%)		360 (23.8%)	2352 (31.0%)
Number of ED visits ^a , n (%)			<0.01 / 0.15		<0.01 / 0.15
0	1756 (85.5%)	8203 (79.9%)		1272 (84.0%)	5971 (78.8%)
1	212 (10.3%)	1405 (13.7%)		179 (11.8%)	1077 (14.2%)
≥2	85 (4.1%)	657 (6.4%)		64 (4.2%)	527 (7.0%)
Number of hospitalizations ^a , n (%)			0.06 / 0.06		<0.01 / 0.13
0	1950 (95.0%)	9611 (93.6%)		1455 (96.0%)	7091 (93.6%)
1	84 (4.1%)	520 (5.1%)		54 (3.6%)	377 (5.0%)
≥2	19 (0.9%)	134 (1.3%)		6 (0.4%)	107 (1.4%)
Preventive care ^a , n(%)			<0.01 / 0.10		0.01 / 0.08
No	1111 (54.1%)	5067 (49.4%)		855 (56.4%)	3979 (52.5%)
Yes	942 (45.9%)	5198 (50.6%)		660 (43.6%)	3596 (47.5%)
Medicaid, n (%)			0.38 / 0.02		0.83 / 0.01
No	1821 (88.7%)	9172 (89.4%)		1314 (86.7%)	6554 (86.5%)
Yes	232 (11.3%)	1093 (10.6%)		201 (13.3%)	1021 (13.5%)
Neighborhood median household income, n(%)			0.19 / 0.06		0.05 / 0.09
< \$40,000	86 (4.2%)	434 (4.2%)		66 (4.4%)	370 (4.9%)
\$40,000-\$59,999	352 (17.1%)	1977 (19.3%)		286 (18.9%)	1626 (21.5%)
\$60,000-\$79,999	559 (27.2%)	2654 (25.9%)		389 (25.7%)	1998 (26.4%)
\$80,000+	1055 (51.4%)	5189 (50.6%)		771 (50.9%)	3572 (47.2%)
Unknown	1 (0.0%)	11 (0.1%)		3 (0.2%)	9 (0.1%)
KPSC physician/employee status, n (%)			<0.01 / 0.34		0.05 / 0.06
No	2012 (98.0%)	9252 (90.1%)		1465 (96.7%)	7241 (95.6%)
Yes	41 (2.0%)	1013 (9.9%)		50 (3.3%)	334 (4.4%)
Specimen type, n (%)			<0.01 / 0.63		<0.01 / 0.33
Nasopharyngeal/oropharyngeal Swab	1809 (88.1%)	6402 (62.4%)		1305 (86.1%)	5545 (73.2%)
Saliva	244 (11.9%)	3863 (37.6%)		210 (13.9%)	2030 (26.8%)

^a Defined in the one year prior to specimen collection date

^b Defined in the two years prior to specimen collection date

^c Defined based on all available medical records from March 1, 2020 to specimen collection date

Medical center area not shown. There were differences in the distribution of the vaccinated and unvaccinated individuals across the 19 medical center areas.

N/A = not applicable